Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

There is no doubt. Positive data, and it pops, negative data and it drops. easy.

It will be an inflection point. The chart says the market is NOT anticipating positive data. I am open minded, but based on the previous data, I do not expect to be wowed.

Regardless, a study with 36 People with AD is useless at this stage of development. The thinking behind why folks will use Lympro is totally flawed, and this thing is just pretty interesting.

A negative or positive study does not tell you much because there are not enough people in the study. Go back to Dr. Kriby's presentation and watch his face when he talks about the number of people in a study, and look at any generally accepted study and there are FAR more than 36 people with the disease in the study, especially with a disease as common as AD.

So, no changes from AMBS on the real science front. They keep rolling out studies that are too small to even consider being science.

Laughable.